Related Experiment Videos
Effect of herbimycin A on renal cancer cell growth
1Department of Urology, National Defense Medical College, Tokorozawa, Japan.
Abstract:
We investigated the effect of herbimycin A on the monolayer growth of 4 human renal cell carcinoma (RCC) cell lines and a normal renal tubular cell line (RTC 13) using MTT [3-(4,5-dimethylthiszol-2,5-diphenyl tetrazolium bromide)] assay. Herbimycin A induced remarkable growth inhibition in each RCC cell line tested, without any morphological changes of the cells. At the concentration of 500 ng/ml, herbimycin A caused more than a 30% growth inhibition in all RCC cells (p < 0.005 vs RTC 13), while less than 7% growth inhibition was observed in RTC 13 at the same herbimycin A concentration. The cell cycle was estimated by analysing DNA (deoxyribonucleic acid) content using a FACS. A DNA histogram of RCC cells treated at herbimycin A showed a block in the cell cycle at the S and G2M phases. However, little effect by herbimycin A on RTC 13 cells was observed. Our results suggest that protein tyrosine kinases inhibitors, like herbimycin A, may offer a new treatment option for RCC patients.
Insights
Herbimycin A significantly inhibits renal cell carcinoma (RCC) growth by halting the cell cycle. This protein tyrosine kinase inhibitor shows promise as a novel treatment for RCC patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Renal cell carcinoma (RCC) is a significant global health concern.
- Targeted therapies are crucial for improving RCC patient outcomes.
- Herbimycin A is a known inhibitor of protein tyrosine kinases.
Purpose of the Study:
- To evaluate the efficacy of herbimycin A in inhibiting the growth of human RCC cell lines.
- To investigate the effects of herbimycin A on the cell cycle of RCC cells.
- To compare the effects of herbimycin A on RCC cells versus normal renal tubular cells.
Main Methods:
- Utilized MTT assay to assess monolayer cell growth inhibition.
- Employed Fluorescence-Activated Cell Sorting (FACS) to analyze DNA content and cell cycle phases.
- Tested herbimycin A on four human RCC cell lines and one normal renal tubular cell line (RTC 13).
Main Results:
- Herbimycin A demonstrated significant growth inhibition in all tested RCC cell lines.
- At 500 ng/ml, herbimycin A caused >30% growth inhibition in RCC cells, with <7% in normal RTC 13 cells (p < 0.005).
- Herbimycin A induced cell cycle arrest at the S and G2M phases in RCC cells, with minimal impact on RTC 13 cells.
Conclusions:
- Herbimycin A effectively inhibits RCC cell proliferation.
- The drug's mechanism involves cell cycle arrest in S and G2M phases.
- Protein tyrosine kinase inhibitors, exemplified by herbimycin A, represent a potential new therapeutic strategy for RCC.